|
Synonyms: IMC-3G3 | Lartruvo® | LY3012207
olaratumab is an approved drug (EMA & FDA (2016))
Compound class:
Antibody
Comment: Olaratumab is a fully human anti-platelet-derived growth factor receptor α (PDGFRα) monoclonal antibody, developed by Eli Lilly (link to Lilly's olaratumab webpage here), originally developed by ImClone Systems, Inc. [2].
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB record. BLAST peptide sequence analysis reveals identical matches with sequences 8 and 16 from patent US8128929, and directly to clone IMC-3G3 [1]. From patent US8128929 it appears that the epitope recognised by olaratumab overlaps the PDGFRα binding sites for PDGF-AA and PDGF-BB. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Loizos N, Huber J. (2012)
Antibodies against PDGFRa. Patent number: US8128929. Assignee: Imclone Llc. Priority date: 17/06/2006. Publication date: 06/04/2012. |
|
2. Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, Rolser R, Malikzay A, Persaud A, Corcoran E et al.. (2005)
Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther, 4 (3): 369-79. [PMID:15767546] |
